2[1]Ohkubo Y, Kishikawa H,Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective-year study. Diabetes Res Clin Pract, 1995,28(3): 103
3[2]UK prospective diabetes study group. Intensive blood glucose con
4[3]trol with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33. Lancet, 1998,352(7) :837
5[6]Owens DR. Repaglinide-prandial glucose regulator: a new class of oral antidiabetic drugs. Diabet Med, 1998,15 ( 4 ): 28
6段文澜,刘红编译.1996年欧洲糖尿病专题会议纪要[C].糖尿病论坛,1997,1:6.
7Anonymous,Repaglinide:A challenge to the sulphonylureas[J].Drugs and Therapy Perspectives 1998;12:1-5.
8Hatorp V,Hasslacher C.Clauson P.Pharmacokinetics of repaglinide in type 2 diabetes patients with and without renal impairment[J].Diabetologia 1999,42(Suppl 1):112.
9UK Prospective Diabetes Study(UKPDS)Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of Complications in pationts with type 2 diabetes(UKPDS 33)[J].Lancet,1998,352:837.
10David RO,Stephen DL,Ikramel,et al.Prandial insulin secretion after administration of asingle preprandial oral does of rerepanglinide in pations with type diabetes Care[J].Increased,2000,23(4):518.
10Schumacher S,Abbasi I,Weise D,et al.Single 2 and multiple dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment[].Eur J Clin Pharmacol,2001,57(2):147-152.
